Skip to main content
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TVRD ISIN · US1407553072 LEI · 549300COVOY41P0GZ881 IL Manufacturing
Open in API
Filings indexed 781 across all filing types
Latest filing 2026-05-08 Interim / Quarterly Rep…
Country US United States of America
Listing IL TVRD

About Tvardi Therapeutics, Inc.

https://tvarditherapeutics.com

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered, small molecule therapies. The company's core approach is targeting STAT3 (Signal Transducer and Activator of Transcription 3), a key regulatory protein implicated in the progression of various diseases. Tvardi's therapeutic pipeline is designed to address conditions with significant unmet medical needs, including various forms of cancer and fibrosis-driven diseases. Its clinical trials are evaluating potential treatments for indications such as liver cancer and idiopathic pulmonary fibrosis (IPF).

Recent filings

Filing Released Lang Actions
10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)
Interim / Quarterly Report
2026-05-08 English
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
Earnings Release Classification · 91% confidence The document is a Form 8-K “Current Report” filed under Item 2.02 “Results of Operations and Financial Condition,” which is used to furnish the company’s press release announcing its quarterly financial results. This corresponds to an initial earnings announcement. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-05-08 English
S-8 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Tvardi Therapeutics, Inc. It is a registration statement under the Securities Act of 1933 for securities to be issued under employee benefit plans (2025 Equity Incentive Plan and 2025 Employee Stock Purchase Plan). The document includes incorporation by reference of prior filings such as the Annual Report on Form 10-K and Current Reports on Form 8-K, but itself is not a financial report or earnings release. It is a regulatory filing related to securities registration for employee plans, not an annual report, earnings release, or other financial report. The document length is over 11,000 characters and contains detailed registration information, exhibits, and signatures. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general SEC filing that does not fit other specific categories like 10-K or ER.
2026-04-01 English
424B3 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
Annual Report Classification · 100% confidence The document is a Form 10-K filing, which is an annual report pursuant to the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2025. It includes detailed sections such as Business, Risk Factors, Legal Proceedings, Management's Discussion and Analysis, Financial Statements, and Executive Compensation, all typical components of a comprehensive annual report. The text explicitly states it is an Annual Report on Form 10-K and contains substantive financial data and analysis. Therefore, the document fits the definition of an Annual Report (10-K).
2026-04-01 English
4 Filing
Director's Dealing
2026-02-02 English
4 Filing
Director's Dealing
2026-02-02 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.